ATC kod: C03DB01, C03EA01
Det saknas kontrollerade studier om skillnader mellan könen avseende effekt, säkerhet och farmakokinetik för amilorid.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of amiloride have been found.
No studies with a clinically relevant sex analysis regarding the dosing of amiloride have been found.
No conclusive studies with a clinically relevant sex analysis regarding the effects of amiloride have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of amiloride have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
A large British randomized, placebo-controlled, single-blind trial compared treatment with hydrochlorothiazide plus amiloride and atenolol in hypertensive older adults (in total 1836 men, 2560 women). Number of deaths from cancer among patients taking diuretic was higher in men than women (0.7% of men 0.3% of women on diuretics compared to 0.5% of men and 0.6% of women with placebo) [1]. These results have unclear relevance today. The cancer mortality rates in UK have fallen by 19% for women and 29% for men between 1990-2016 [2].
Fler kvinnor än män hämtade ut tabletter innehållande amilorid (ATC-kod C03DB01) på recept i Sverige år 2018, totalt 2 913 kvinnor och 1 810 män. Det motsvarar 0,6 respektive 0,4 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 85 år och äldre hos båda könen. I genomsnitt var tabletter innehållande amilorid 1,6 gånger vanligare hos kvinnor [3].
Uppdaterat: 2020-08-28
Litteratursökningsdatum: 2019-03-11
Faktagranskat av: Mia von Euler
Godkänt av: Karin Schenck-Gustafsson